Search Result

Results for "

B-cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BCL6 (2) Acyltransferase (1) ADC Antibody (5) ADC Linker (2) Akt (2) Amyloid-β (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (4) Apoptosis (36) Autophagy (5) Bacterial (6) Bcl-2 Family (17) Bcr-Abl (1) BCRP (1) BMX Kinase (1) Btk (25) Caspase (2) Cathepsin (2) CD19 (8) CD20 (7) CD22 (2) CD28 (1) CD3 (4) CD73 (1) CD74 (1) CDK (3) Dengue virus (2) Deubiquitinase (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (1) Drug Metabolite (4) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (1) EBI2/GPR183 (1) EGFR (2) Endogenous Metabolite (7) Flavivirus (2) FLT3 (1) Fungal (1) Galectin (1) HCV (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (2) Histone Methyltransferase (6) HSV (1) IAP (1) IFNAR (1) IKK (1) Interleukin Related (2) IRAK (7) Isotope-Labeled Compounds (4) JAK (4) LAG-3 (1) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (2) Liposome (3) LPL Receptor (1) MALT1 (3) MAP4K (2) MDM-2/p53 (2) MicroRNA (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (3) MMP (1) MNK (1) Molecular Glues (6) Necroptosis (1) NF-κB (2) p38 MAPK (1) Parasite (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (6) Pim (1) Potassium Channel (1) PPAR (1) PROTACs (7) Proteasome (1) Pyroptosis (1) RABV (1) Ras (1) Ser/Thr Protease (1) SHMT (1) Survivin (1) Syk (3) TNF Receptor (6) Toll-like Receptor (TLR) (6) VEGFR (1) Virus Protease (1) β-catenin (3) γ-secretase (1)
By Research Areas:	Cancer (152) Cardiovascular Disease (1) Endocrinology (1) Infection (10) Inflammation/Immunology (79) Metabolic Disease (5) Neurological Disease (5)
Click Chemistry:	Alkynes (1)

202

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

106

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

PCLX-001 1 Publications Verification	Others	Cancer
PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC₅₀s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 exhibits anti-tumor activity and inhibits early B-cell receptor (BCR) signaling, can be used to B-cell malignancies research .

Blontuvetmab AT 004; VT 007	CD20	Cancer
Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix	Apoptosis	Inflammation/Immunology Cancer
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

SGR-1505	MALT1	Cancer
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .

Blisibimod A 623; AMG 623	TNF Receptor	Inflammation/Immunology
Blisibimod (A 623) is a potent and selective tetravalent inhibitor of B-cell activating factor (BAFF). Blisibimod can be used for the research of systemic lupus erythematosus (SLE) .

Z-VRPR-FMK	MALT1	Cancer
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28	Cancer
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .

BCL6-IN-9	Bcl-2 Family	Cancer
BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC₅₀ of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .

SHMT-IN-2	SHMT	Endocrinology Cancer
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC₅₀ values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .

NSC10010 hydrochloride	Bacterial Necroptosis HSV	Infection Cancer
NSC10010 hydrochloride inhibits gammaherpesvirus associated B-lymphomas growth through activation of NF-kB and c-Myc-mediated signaling pathways. NSC10010 hydrochloride induces necrotic cell death in gammaherpesvirus infected B-cells. NSC10010 hydrochloride is also an inhibitor of Mtb ClpC1 ATPase .

BTK-IN-6	Btk	Neurological Disease Inflammation/Immunology Cancer
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) .

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor	Inflammation/Immunology
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research .

TMX-2164	Bcl-2 Family	Cancer
TMX-2164 is a potent, irreversible B-cell lymphoma 6 (BCL6) inhibitor with an IC₅₀ value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

UBX-382	Btk	Cancer
UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins and shows anti-cancer activity in murine xenograft models of TMD-8 cells .

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

DPPY	JAK Btk EGFR	Inflammation/Immunology Cancer
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

Parsaclisib INCB050465; IBI-376	PI3K	Cancer
Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies .

Parsaclisib hydrochloride INCB050465 hydrochloride; IBI-376 hydrochloride	PI3K	Cancer
Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies .

Cobomarsen MRG-106	MicroRNA	Cancer
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma .

Cerdulatinib hydrochloride 5 Publications Verification PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies .

Avadomide 5+ Cited Publications CC 122	E1/E2/E3 Enzyme Apoptosis Molecular Glues	Inflammation/Immunology Cancer
Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity and induces apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities .

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

Lixumistat IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism	Cancer
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .

Aderbasib INCB007839; INCB7839	MMP	Cancer
Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 ⁺ breast cancer, gliomas, et al .

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

Moxetumomab pasudotox CAT 8015; HA 22; Anti-Human CD22 Recombinant Antibody	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .

Pinobanksin 3,5,7-Trihydroxyflavanone	Apoptosis	Others
Pinobanksin has apoptotic induction in a B-cell lymphoma cell line .

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

Voruciclib hydrochloride	CDK	Cancer
Voruciclib hydrochloride is an orally active and selective CDK inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

Voruciclib	CDK	Cancer
Voruciclib is an orally active and selective CDK inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

EZM0414 3 Publications Verification	Histone Methyltransferase	Cancer
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC₅₀=18 nM in SETD2 biochemical assay; IC₅₀=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

IRAK4-IN-27	IRAK Apoptosis	Cancer
IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC₅₀ of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .

PI3Kδ/γ-IN-2	PI3K	Cancer
PI3Kδ/γ-IN-2 is a potent PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies .

BGB-8035	Btk	Inflammation/Immunology Cancer
BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC₅₀s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

PTD10	PROTACs Btk	Cancer
PTD10 is a highly potent PROTAC BTK degrader (DC₅₀: 0.5 nM, K_D: 2.28 nM). PTD10 degrades BTK in Ramos and JeKo-1 cells with DC₅₀s of 0.5 and 0.6 nM respectively. PTD10 inhibits cell growth, and induces cell apoptosis via activation of the caspase-dependent pathway and mitochondrial pathway. PTD10 can be used for research of B-cell dysregulation .

QL-X-138	Flavivirus Dengue virus Btk MNK	Infection Cancer
QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC₅₀s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC₅₀ of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies .

Rufloxacin hydrochloride MF-934 hydrochloride	Bacterial Antibiotic	Infection
Rufloxacin hydrochloride (MF-934 hydrochloride) is a fluoroquinolone antibacterial, inhibits B-cell differentiation in human mononuclear cells, inhibits Topo.

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

Thalidomide-piperazine-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-piperazine-Boc is an intermediate that can be used in the synthesis of B-cell lymphoma 6 protein (BCL6) PROTAC .

Cat. No.	Product Name

HY-L014

NF-κB Signaling Compound Library

798 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 798 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

HY-L156

Autoimmune Disease Compound Library

454 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 454 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Type

HY-E70048

beta-1,3-N-Acetylgalactosaminyltransferase (LgtD) Gb4 synthetase	Biochemical Assay Reagents
beta-1,3-N-Acetylgalactosaminyltransferase (LgtD) (Gb4 synthetase) expressed by mature/activated B cells .

HY-153234

CD19 car circRNA-LNP

Drug Delivery

CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

HY-153233

CD19 car mRNA-LNP

Drug Delivery

CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

Cat. No.	Product Name	Target	Research Area

HY-125153

Bursin	Peptides	Others
Bursin is a peptide that can be isolated from the bursa of Fabricius of chicken. Bursin induces the phenotypic differentiation of mammalian and avian B precursor cells. Bursin also increases cyclic guanosine monophosphate in cells of the human B-cell line Daudi .

HY-P1700

BCMA72-80	Peptides	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P5332

Aβ1-14-εK-HBsAg3 Th UB311 immunogen II	Peptides	Others
Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P5333

Aβ1-14-εK-KKK-MvF5 Th UB311 immunogen I	Peptides	Others
Aβ1-14-εK-KKK-MvF5 Th (UB311 immunogen I) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P5472

Tumour-associated MUC1 epitope	Peptides	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-P4802

Pam3-Cys-Ala-Gly

Peptides Inflammation/Immunology

Pam3-Cys-Ala-Gly, a synthetic bacterial lipopeptide, is a potent macrophage and B cell activator .

HY-P0286

OVA Peptide (323-339) 4 Publications Verification	Peptides	Inflammation/Immunology
OVA Peptide (323-339) represents a T and B cell epitope of Ovalbumin (Ova), which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice.

HY-P0085

Splenopentin diacetate	Peptides	Inflammation/Immunology
Splenopentin diacetate is a synthetic immunomodulating pentapeptide corresponding to the residues 32-36 of the splenic hormone splenin. Splenopentin diacetate influences both early T and B cell differentiation, to increase the number of antibody-forming cells in mice after gamma irradiation .

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P3638

Binetrakin	Peptides	Inflammation/Immunology
Binetrakin (Interleukin 4 (human)) is a T lymphocyte-derived pleiotrophic cytokine that affects a variety of cell types including B cells and T cells. Binetrakin induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Binetrakin can be used for the research of many biological .

HY-P1854

β-Amyloid (1-9)	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-P10109A

G6PI 325-339 (human) (hydrochloride) hG6PI (325-339) (hydrochloride)	Peptides	Inflammation/Immunology
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-P10109

G6PI 325-339 (human) hG6PI (325-339)	Peptides	Inflammation/Immunology
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-P5448

MOG (92–106), mouse, rat	Peptides	Others
MOG (92–106), mouse, rat is a biological active peptide. (This is amino acids 92 to 106 fragment of the myelin oligodendrocyte glycoprotein (MOG) from mouse/rat. Mice with MOG (92–106)-induced experimental autoimmune encephalomyelitis develop extensive B cell reactivity against secondary myelin antigens. Despite the fact that this MOG peptide induces only weak T cell responses, MOG-induced autoimmunity is very severe. This peptide is encephalitogenic in SJL mice, DA rats, and rhesus monkeys.)

HY-P5295

Cy3-Ova (323-339)	Peptides	Others
Cy3-Ova (323-339) is an Cy3 labled OVA Peptide (323-339) (HY-P0286). Cy3 is a fluorescent dye belonging to the Cyanine family and is a fluorescent light product of Cy5. Cyanine is commonly used in fluorescence microscopy, cell imaging, and molecular biology experiments. OVA Peptide (323-339) represents the T and B cell epitopes of ovalbumin (OVA). OVA Peptide (323-339) has limited immunogenic efficacy in activating OVA-sensitized and attacked mouse spleen cells .

HY-P5488

BDC2.5 Mimotope 1040-63	Peptides	Others
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)

Cat. No.	Product Name	Target	Research Area

HY-P99483

Blontuvetmab

AT 004; VT 007
CD20 Cancer

Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P9981

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix	Apoptosis	Inflammation/Immunology Cancer
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28	Cancer
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .

HY-P99501

Zuberitamab

HS006
CD20 Cancer

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-P99482

Blisibimod A 623; AMG 623	TNF Receptor	Inflammation/Immunology
Blisibimod (A 623) is a potent and selective tetravalent inhibitor of B-cell activating factor (BAFF). Blisibimod can be used for the research of systemic lupus erythematosus (SLE) .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor	Inflammation/Immunology
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99400

Samalizumab ALXN 6000	Inhibitory Antibodies	Cancer
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99255

Moxetumomab pasudotox CAT 8015; HA 22; Anti-Human CD22 Recombinant Antibody	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99851

Detumomab SPECIFID	Inhibitory Antibodies	Cancer
Detumomab is a mouse monoclonal antibody targeting *human B-cell* lymphoma**. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

HY-P99055

Urelumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	Inhibitory Antibodies	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99563

Tibulizumab LY 3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM) .

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .

HY-P99568

Telitacicept RC18	Inhibitory Antibodies	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99711

Loncastuximab RB4v1.2	CD19	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .

HY-P99731

Milatuzumab 1 Publications Verification hLL1; MEDI-115	CD74	Cancer
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .

HY-P9963

Blinatumomab Anatumomab	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia .

HY-P99038

Odronextamab	CD20	Inflammation/Immunology Cancer
Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells .

HY-P99113

Inebilizumab	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-P99321

Teneliximab BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody	TNF Receptor	Inflammation/Immunology Cancer
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .

HY-P99313

Quilizumab Anti-Human NGcGM3 Recombinant Antibody	Apoptosis	Inflammation/Immunology
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research .

HY-P99042

Polatuzumab	ADC Antibody	Cancer
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .

HY-P99412

Lusvertikimab OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .

HY-P9960

Ocrelizumab Ocrevus	CD20	Inflammation/Immunology
Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS) .

HY-P99487

Briobacept BR 3FC	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

Species:	Human (52) Virus (6) Rhesus Macaque (5) Mouse (27) Rat (6) Cynomolgus (8) Dog (1) Canine (1)
Tag:	His (67) Tag Free (17) Avi (7) GST (2) Trx (2) Fc (19) Flag (1)
Source:	HEK293 (61) E. coli Cell-free (3) CHO (2) Sf9 insect cells (6) P. pastoris (3) E. coli (31)

Cat. No.	Compare	Product Name	Species	Source

HY-P70644

	IL-4 Protein, Mouse Interleukin-4; B-cell IgG differentiation factor; B-cell growth factor 1; B-cell stimulatory factor 1; IGG1 induction factor; Lymphocyte stimulatory factor 1; IL-4; BSF-1	Mouse	E. coli
	IL-4 Protein, Mouse is a pleiotropic cytokine that regulates diverse T and B cell responses including cell proliferation, survival and gene expression.

HY-P70653

	IL-4 Protein, Mouse (HEK293, His) 4 Publications Verification Interleukin-4; IL-4; IL4; B-cell IgG differentiation factor; B-cell growth factor 1; B-cell stimulatory factor 1; BSF-1; IGG1 induction factor; Lymphocyte stimulatory factor 1	Mouse	HEK293
	IL-4 Protein, Mouse (HEK293, His) is a pleiotropic cytokine that regulates diverse T and B cell responses including cell proliferation, survival and gene expression. IL-4 Protein, Mouse (HEK293, His) is a recombinant mouse interleukin-4 (rhIL-4) expressed in HEK 293 cells with a His tag.

HY-P70653A

	IL-4 Protein, Mouse (HEK293, C-His) Interleukin-4; B-cell IgG differentiation factor; B-cell growth factor 1; B-cell stimulatory factor 1; IGG1 induction factor; Lymphocyte stimulatory factor 1; IL-4; BSF-1	Mouse	HEK293
	Interleukin 4 (IL-4) Protein is a pleiotropic cytokine secreted primarily by mast cells, T-cells, eosinophils, and basophils that plays a role in regulating antibody production, hematopoiesis and inflammation, and the development of effector T-cell responses. IL-4 participates in STAT6 signaling and regulates the expression of MHC II, IgE, IgG1 amd CD23. IL-4 Protein, Mouse (HEK293, C-His) is the recombinant mouse-derived IL-4 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of IL-4 Protein, Mouse (HEK293, C-His) is 120 a.a., with molecular weight of ~18 kDa.

HY-P7132

	BCMA/TNFRSF17 Protein, Human rHuBCMA; TNFRSF17; CD269; B-cell maturation protein; BCM	Human	E. coli
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human is a recombinant protein consisting of 50 amino acids (A5-A54) and is produced in E. coli cells.

HY-P75474

	BLNK Protein, Human (HEK293, His) B-cell linker protein; SLP-65; BLNK; BASH; SLP65	Human	HEK293
	BLNK proteins function as central linkers downstream of the B cell receptor (BCR), bridging SYK kinases to various signaling pathways and regulating B cell function and development. It activates ERK/EPHB2, MAP kinase p38 and JNK, regulates AP1 activation, and plays a key role in NF-kappa-B and NFAT activation. BLNK Protein, Human (HEK293, His) is the recombinant human-derived BLNK protein, expressed by HEK293 , with N-His labeled tag. The total length of BLNK Protein, Human (HEK293, His) is 456 a.a., with molecular weight of 95-100 kDa.

HY-P73214

	IL-4 Protein, Canine 1 Publications Verification Interleukin-4; IL-4; B-cell stimulatory factor 1; BSF-1	Canine	E. coli
	The IL-4 protein actively participates in the B cell activation process, acting as a costimulator for DNA synthesis. It induces the expression of class II MHC molecules on resting B cells, enhances IgE and IgG1 secretion and cell surface expression, and modulates CD23 expression on lymphocytes and monocytes. IL-4 Protein, Canine is the recombinant canine-derived IL-4 protein, expressed by E. coli , with N-Met labeled tag. The total length of IL-4 Protein, Canine is 108 a.a., with molecular weight of 12-14 kDa.

HY-P72711

	CD72 Protein, Human (N-Trx-6His) B-cell differentiation antigen CD72; Lyb-2; CD72	Human	E. coli
	CD72 Protein plays a key role in orchestrating B-cell proliferation and differentiation, forming homodimers with disulfide linkages and interacting with CD5. It engages in tyrosine phosphorylation interactions with PTPN6/SHP-1, indicating its modulation of cellular responses through phosphorylation-based regulatory mechanisms. This underscores the multifaceted role of CD72 in the dynamic landscape of B-cell function and signaling. CD72 Protein, Human (N-Trx-6His) is the recombinant human-derived CD72 protein, expressed by E. coli , with N-Trx, N-His labeled tag. The total length of CD72 Protein, Human (N-Trx-6His) is 110 a.a., with molecular weight of 26-35 kDa.

HY-P77510

	IL-4 Protein, Human (Biotinylated) Interleukin-4; IL-4; B-cell stimulatory factor 1; BSF-1	Human	E. coli
	The IL-4 protein is primarily secreted by mast cells, T cells, eosinophils, and basophils and is critical for antibody production, hematopoiesis, and immune responses. It induces MHC class II expression on B cells, enhances IgE and IgG1 secretion, and modulates CD23 and IL31RA expression. IL-4 Protein, Human (Biotinylated) is the recombinant human-derived IL-4 protein, expressed by E. coli , with tag free. The total length of IL-4 Protein, Human (Biotinylated) is 129 a.a., with molecular weight of ~.

HY-P7537

	BCL2 Protein, Human (His) rHuApoptosis Regulator Bcl-2, His; B-cell Lymphoma 2; Apoptosis Regulator Bcl-2	Human	E. coli
	BCL2 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Proteins of the Bcl-2 family are important regulators of apoptosis in many tissues of the embryo and adult.

HY-P72703

	CD83 Protein, Human (HEK293, Fc) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Human	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Human (HEK293, Fc) is the recombinant human-derived CD83 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD83 Protein, Human (HEK293, Fc) is 124 a.a., with molecular weight of 50-60 kDa.

HY-P74260

	CD83 Protein, Mouse (HEK293, His) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Mouse	HEK293
	CD83 protein may be a key player in antigen presentation and cellular interactions during lymphocyte activation, highlighting its importance in immune processes. It potentially orchestrates antigen presentation and acts as a monomer. Investigating CD83's mechanisms in antigen presentation and lymphocyte activation could provide insights into its crucial role in shaping immune responses and cellular interactions within the immune system. CD83 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD83 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD83 Protein, Mouse (HEK293, His) is 133 a.a., with molecular weight of 25-35 kDa.

HY-P75375

	CD83 Protein, Rat (HEK293, His) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Rat	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Rat (HEK293, His) is the recombinant rat-derived CD83 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD83 Protein, Rat (HEK293, His) is 134 a.a., with molecular weight of 27-35 kDa.

HY-P75376

	CD83 Protein, Rat (HEK293, Fc) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Rat	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD83 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD83 Protein, Rat (HEK293, Fc) is 134 a.a., with molecular weight of ~53 kDa.

HY-P75377

	CD83 Protein, Human (HEK293, His) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Human	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Human (HEK293, His) is the recombinant human-derived CD83 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD83 Protein, Human (HEK293, His) is 124 a.a., with molecular weight of 20-30 kDa.

HY-P76245

	CD83 Protein, Cynomolgus (HEK293, Fc) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Cynomolgus	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD83 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD83 Protein, Cynomolgus (HEK293, Fc) is 143 a.a., with molecular weight of 45-55 & 34 KDa, respectively.

HY-P76246

	CD83 Protein, Cynomolgus (HEK293, His) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Cynomolgus	HEK293
	The CD83 protein is involved in antigen presentation or mediating cell interactions following lymphocyte activation. The specific mechanisms by which CD83 affects these processes in the immune response have not been fully elucidated. CD83 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD83 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD83 Protein, Cynomolgus (HEK293, His) is 143 a.a., with molecular weight of ~19 & 21 & 27 KDa, respectively.

HY-P70560

	Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) Siglec-2; CD22; B-cell Receptor CD22	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) is 668 a.a., with molecular weight of 120-150 kDa.

HY-P700216AF

	Animal-Free IL-6 Protein, Mouse (His) IFN-β2; B-cell Differentiation Factor (BCDF); BSF-2; HPGF; HSF; MGI-2	Mouse	E. coli
	IL-6 protein is involved in various functions such as immunity, tissue regeneration and metabolism. Animal-Free IL-6 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeIL-6 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IL-6 Protein, Mouse (His) is 187 a.a., with molecular weight of ~22.7 kDa.

HY-P72019

	Siglec-2/CD22 Protein, Human (HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Human (HEK293, His) is 668 a.a., with molecular weight of 77-110 kDa.

HY-P72474A

	Siglec-2/CD22 Protein, Mouse (HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; Lyb-8	Mouse	HEK293
	Siglec-2/CD22 is a B cell surface receptor that mediates B cell interactions and is involved in B cell localization within lymphoid tissues. It selectively binds α-2,6-linked sialic acids, including CD45, and its sialic acid recognition site may be regulated by cis interactions. Siglec-2/CD22 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (HEK293, His) is 681 a.a., with molecular weight of 95-130 kDa.

HY-P72704

	CD83 Protein, Mouse (113a.a, HEK293, Fc) B-cell activation protein; CD83 antigen; hCD83; CD83; BL11	Mouse	HEK293
	CD83 protein may be a key player in antigen presentation and cellular interactions during lymphocyte activation, highlighting its importance in immune processes. It potentially orchestrates antigen presentation and acts as a monomer. Investigating CD83's mechanisms in antigen presentation and lymphocyte activation could provide insights into its crucial role in shaping immune responses and cellular interactions within the immune system. CD83 Protein, Mouse (113a.a, HEK293, Fc) is the recombinant mouse-derived CD83 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD83 Protein, Mouse (113a.a, HEK293, Fc) is 113 a.a., with molecular weight of 55-65 kDa.

HY-P72707

	CD79B Protein, Mouse (HEK293, Fc) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Mouse	HEK293
	CD79B protein, together with CD79A, initiates the B-cell antigen receptor complex (BCR) signaling cascade, which is critical for complex internalization and transport to late endosomes, promoting antigen presentation. CD79B enhances CD79A phosphorylation, possibly recruiting kinases or protective proteins. CD79B Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD79B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD79B Protein, Mouse (HEK293, Fc) is 133 a.a., with molecular weight of 50-65 kDa.

HY-P72709

	CD79A Protein, Human (HEK293, His) B-cell antigen receptor complex-associated protein alpha chain; CD79a; IGA; MB1	Human	HEK293
	The CD79A protein is critical for initiating the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. It promotes internalization, transport to late endosomes, and antigen presentation of BCR complexes. CD79A Protein, Human (HEK293, His) is the recombinant human-derived CD79A protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD79A Protein, Human (HEK293, His) is 111 a.a., with molecular weight of 25-40 kDa.

HY-P75383

	CD79A Protein, Mouse (HEK293, Fc) B-cell antigen receptor complex-associated protein alpha chain; CD79a; IGA; MB1	Mouse	HEK293
	CD79A cooperates with CD79B to initiate the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. This results in complex internalization, transport and antigen presentation. CD79A Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD79A protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD79A Protein, Mouse (HEK293, Fc) is 109 a.a., with molecular weight of ~39 kDa.

HY-P75626

	CD22 Protein, Rhesus Macaque (HEK293, Fc) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rhesus Macaque	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. CD22 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD22 Protein, Rhesus Macaque (HEK293, Fc) is 686 a.a., with molecular weight of ~102.1 kDa.

HY-P75627

	CD22 Protein, Rhesus Macaque (HEK293, His) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rhesus Macaque	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. CD22 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD22 Protein, Rhesus Macaque (HEK293, His) is 686 a.a., with molecular weight of ~76.5 kDa.

HY-P75658

	CD79B Protein, Rat (HEK293, Fc) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Rat	HEK293
	CD79B Protein, also known as B29 or Igβ, is an essential component of the B cell receptor along with immunoglobulin and mb1 (Igα, CD79a) and is absolutely required for B cell development. Rat CD79B protein comprises 228 amino acids, and its amino acid sequence is 85 and 69% identical with the mouse and human counterparts, respectively. The B-cell antigen receptor (BCR) signaling component Igβ (CD79B) and the co-receptor CD19 act as an alternative B-cell signaling module that promotes the survival of B lymphoma and normal B cells via integrated ITAM/PI3K signaling. The loss of CD79B causes a block in N-glycan maturation and accumulation of immature proteins. CD79B Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD79B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD79B Protein, Rat (HEK293, Fc) is 133 a.a., with molecular weight of ~50 kDa.

HY-P75659

	CD79B Protein, Rat (HEK293, His) B-cell antigen receptor complex-associated protein beta chain; CD79b; B30; IGB	Rat	HEK293
	CD79B Protein, also known as B29 or Igβ, is an essential component of the B cell receptor along with immunoglobulin and mb1 (Igα, CD79a) and is absolutely required for B cell development. Rat CD79B protein comprises 228 amino acids, and its amino acid sequence is 85 and 69% identical with the mouse and human counterparts, respectively. The B-cell antigen receptor (BCR) signaling component Igβ (CD79B) and the co-receptor CD19 act as an alternative B-cell signaling module that promotes the survival of B lymphoma and normal B cells via integrated ITAM/PI3K signaling. The loss of CD79B causes a block in N-glycan maturation and accumulation of immature proteins. CD79B Protein, Rat (HEK293, His) is the recombinant rat-derived CD79B protein, expressed by HEK293 , with C-His labeled tag. The total length of CD79B Protein, Rat (HEK293, His) is 133 a.a., with molecular weight of ~28 kDa.

HY-P77537

	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) is 687 a.a., with molecular weight of ~76.6 KDa.

HY-P72708

	CD79B Protein, Rhesus Macaque (HEK293, His) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Rhesus Macaque	HEK293
	CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD79B protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD79B Protein, Rhesus Macaque (HEK293, His) is 132 a.a., with molecular weight of 20-30 kDa.

HY-P75385

	CD79 Protein, Mouse (HEK293, His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Mouse	HEK293
	CD79A, collaborating with CD79B, initiates the B-cell antigen receptor complex (BCR) signal cascade upon antigen binding. This leads to complex internalization, trafficking, and antigen presentation. Essential for BCR surface expression and B-cell differentiation, CD79A stimulates SYK activation, binds BLNK, and enhances Src-family kinase activity. It represses BCR signaling during immature B-cell development. As a disulfide-linked complex, CD79A forms the BCR with alpha/beta chain heterodimer and membrane-bound immunoglobulin. CD79 Protein, Mouse (HEK293, His) is a recombinant protein dimer complex containing mouse-derived CD79 protein, expressed by HEK293, with C-His labeled tag. CD79 Protein, Mouse (HEK293, His), has molecular weight of ~34.6 & 28.3 & 24.1 kDa, respectively.

HY-P700131AF

	Animal-Free IL-5 Protein, Human (His) Interleukin-5; B-cell differentiation factor I; EosinophIL differentiation factor; T-cell replacing factor; TRF; IL5	Human	E. coli
	The IL-5 Protein, predominantly expressed by T-lymphocytes and NK cells, is crucial for eosinophil survival, differentiation, and chemotaxis. It also affects B-cells, inducing immunoglobulin production, growth, and differentiation. IL-5 Protein activates kinases like LYN, SYK, and JAK2, which signal through RAS-MAPK and JAK-STAT5 pathways. It exists as a disulfide-linked homodimer and interacts with IL5RA and CSF2RB subunits. Animal-Free IL-5 Protein, Human (His) is the recombinant human-derived animal-FreeIL-5 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IL-5 Protein, Human (His) is 115 a.a., with molecular weight of ~14.09 kDa.

HY-P75386A

CD79 Protein, Human (HEK293, His)

B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB
Human HEK293

HY-P72474

	Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; Lyb-8	Mouse	HEK293
	Siglec-2/CD22 Protein mediates B-cell B-cell interaction and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) is 681 a.a., with molecular weight of 100-120 kDa.

HY-P73646

	Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Mouse	HEK293
	Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is a Siglec of ~140 kDa with seven Ig-like domains and is expressed in a B-cell lineage-specific fashion, starting at the pre-B cell stage. CD22 is associated with membrane-bound IgM on the surface of B cells. Siglec-2 (CD22) specifically recognizes 伪2.6 sialic acid-containing glycans. Siglec-2 negatively regulates B cell antigen receptor (BCR) signaling by recruitment and activation of SH2-containing phosphatase 1 (SHP-1), which counteracts the phospharylation-mediated activation of signaling molecules by dephosphorylation, and reduces Ca²⁺ signaling by regulating the activity of the Ca²⁺ pump PMCA. Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is 690 a.a., with molecular weight of ~125 kDa.

HY-P73648

	Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) is 512 a.a., with molecular weight of 90-100 kDa.

HY-P75386

	CD79 Protein, Human (HEK293, Flag-His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Human	HEK293
	CD79A Protein is crucial for initiating the B-cell antigen receptor complex (BCR) signal transduction cascade upon antigen binding. It facilitates BCR complex internalization, trafficking to late endosomes, and antigen presentation. CD79A ensures BCR surface expression, pro- and pre-B-cell differentiation, and autophosphorylation of SYK by binding to BLNK. It interacts with FYN and LYN kinases, enhancing their activity. CD79A, forming a disulfide-linked heterodimer with CD79B, constitutes the BCR complex. It interacts with SYK and BLNK, orchestrating essential signaling events in B-cell development. CD79 Protein, Human (HEK293, Flag-His) is a recombinant protein dimer complex containing human-derived CD79 protein, expressed by HEK293, with C-His, C-Flag labeled tag. CD79 Protein, Human (HEK293, Flag-His), has molecular weight of ~37.5 kDa.

HY-P70612

	IL-5 Protein, Human (HEK293, His) 1 Publications Verification Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5	Human	HEK293
	The IL-5 Protein, predominantly expressed by T-lymphocytes and NK cells, is crucial for eosinophil survival, differentiation, and chemotaxis. It also affects B-cells, inducing immunoglobulin production, growth, and differentiation. IL-5 Protein activates kinases like LYN, SYK, and JAK2, which signal through RAS-MAPK and JAK-STAT5 pathways. It exists as a disulfide-linked homodimer and interacts with IL5RA and CSF2RB subunits. IL-5 Protein, Human (HEK293, His) is the recombinant human-derived IL-5 protein, expressed by HEK293 , with C-His labeled tag. The total length of IL-5 Protein, Human (HEK293, His) is 115 a.a., with molecular weight of ~20.0 kDa.

HY-P70746

	IL-5 Protein, Mouse (HEK293, His) Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5	Mouse	HEK293
	IL-5 protein is expressed by T lymphocytes and NK cells and regulates eosinophils, affecting their survival, differentiation and chemotaxis. In addition, IL-5 stimulates immunoglobulin production, growth, and differentiation of activated and resting B cells. IL-5 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IL-5 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IL-5 Protein, Mouse (HEK293, His) is 113 a.a., with molecular weight of 14-26 kDa.

HY-P71859

	IL-4 Protein, Rhesus macaque IL4Interleukin-4; IL-4; B-cell stimulatory factor 1; BSF-1; Lymphocyte stimulatory factor 1	Rhesus Macaque	E. coli
	IL-4 protein actively engages in B-cell activation, serving as a costimulator for DNA synthesis, inducing class II MHC molecule expression, and enhancing IgE and IgG1 secretion. It regulates CD23 expression on lymphocytes and monocytes, positively influences IL31RA expression in macrophages, and induces autophagy in dendritic cells through mTORC1 signaling interference and RUFY4 induction. IL-4 Protein, Rhesus macaque is the recombinant Rhesus Macaque-derived IL-4 protein, expressed by E. coli , with tag free. The total length of IL-4 Protein, Rhesus macaque is 129 a.a., with molecular weight of ~14.9 kDa.

HY-P72387

	IL-5 Protein, Human (Biotinylated, HEK293, His-Avi) Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5	Human	HEK293
	The IL-5 Protein, predominantly expressed by T-lymphocytes and NK cells, is crucial for eosinophil survival, differentiation, and chemotaxis. It also affects B-cells, inducing immunoglobulin production, growth, and differentiation. IL-5 Protein activates kinases like LYN, SYK, and JAK2, which signal through RAS-MAPK and JAK-STAT5 pathways. It exists as a disulfide-linked homodimer and interacts with IL5RA and CSF2RB subunits. IL-5 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived IL-5 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of IL-5 Protein, Human (Biotinylated, HEK293, His-Avi) is 115 a.a., with molecular weight of 18-24 kDa.

HY-P73215

	IL-4 Protein, Mouse (Q136D, Y139D, sf9, His) Interleukin-4; IL-4; B-cell stimulatory factor 1; BSF-1	Mouse	Sf9 insect cells
	Interleukin 4 (IL-4) Protein is a pleiotropic cytokine secreted primarily by mast cells, T-cells, eosinophils, and basophils that plays a role in regulating antibody production, hematopoiesis and inflammation, and the development of effector T-cell responses. IL-4 participates in STAT6 signaling and regulates the expression of MHC II, IgE, IgG1 amd CD23. IL-4 Protein, Mouse (Q136D, Y139D, sf9, His) is the recombinant mouse-derived IL-4 protein, expressed by Sf9 insect cells , with C-His labeled tag and Q136D, Y139D, , , mutation. The total length of IL-4 Protein, Mouse (Q136D, Y139D, sf9, His) is 140 a.a., with molecular weight of ~19 kDa.

HY-P77539

	Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) is 512 a.a., with molecular weight of ~58.5 KDa.

HY-P700215AF

	Animal-Free IL-5 Protein, Mouse (His) Interleukin-5; IL-5; B-cell differentiation factor I; EosinophIL differentiation factor; T-cell replacing factor; TRF; IL5	Mouse	E. coli
	IL-5 protein is expressed by T lymphocytes and NK cells and regulates eosinophils, affecting their survival, differentiation and chemotaxis. In addition, IL-5 stimulates immunoglobulin production, growth, and differentiation of activated and resting B cells. Animal-Free IL-5 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeIL-5 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IL-5 Protein, Mouse (His) is 113 a.a., with molecular weight of ~13.93 kDa.

HY-P70445

	IL-4 Protein, Human Maximum Cited Publications 11 Publications Verification Interleukin-4; IL-4; B-cell Stimulatory Factor 1; BSF-1; Binetrakin; Lymphocyte Stimulatory Factor 1; Pitrakinra; IL4	Human	E. coli
	IL-4 Protein, Human is a potent lymphoid cell growth factor, which stimulates the growth and survivability of B-cells and T-cells.

HY-P70778

	BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, His) Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma	Cynomolgus	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, His) is a recombinant protein with a C-Terminal His label, It consists of 53 amino acids (M1-A53) and is produced in HEK293 cells.

HY-P70827

	BCMA/TNFRSF17 Protein, Human (HEK293, mFc) Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma	Human	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human (HEK293, mFc) is a recombinant protein with a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

HY-P72342

	BCMA/TNFRSF17 Protein, Human (Biotinylated, HEK293, Fc-Avi) Tumor necrosis factor receptor superfamily member 17; TNFRSF17; B-cell maturation protein; CD269	Human	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human (Biotinylated, HEK293, Fc-Avi) is a biotinylated recombinant protein with a C-Terminal Avi label and a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

HY-P75430

	Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rat	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His) is 692 a.a., with molecular weight of ~76.7 kDa.

HY-P75431

	Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rat	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc) is 692 a.a., with molecular weight of ~102 kDa.

Cat. No.	Product Name	Application	Reactivity

HY-P82537

BLNK Antibody (YA2282) BLNK; BASH; SLP65; B-cell linker protein; B-cell adapter containing a SH2 domain protein; B-cell adapter containing a Src homology 2 domain protein; Cytoplasmic adapter protein; Src homology 2 domain-containing leukocyte protein of 65 kDa	WB, IP	Human, Mouse, Rat

HY-P81434

BANK1 Antibody (YA1179)

BANK1; B-cell scaffold protein with ankyrin repeats
IHC-P Human
HY-P81756

BCMA Antibody (YA1501)

TNFRSF17; BCM; BCMA; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269
FC, ELISA Human

HY-P81443

Bcl10 Antibody (YA1188) BCL10; CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; cellular homolog	IHC-P	Human

HY-P81536

Bcl6 Antibody (YA1281) BCL6; BCL5; LAZ3; ZBTB27; ZNF51; B-cell lymphoma 6 protein; BCL-6; B-cell lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51	IHC-P	Human

HY-P80576

BTK Antibody (YA816) BTK; AGMX1; ATK; BPK; Tyrosine-protein kinase BTK; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IP	Human
BTK Antibody (YA816) is a non-conjugated and Mouse origined monoclonal antibody about 76 kDa, targeting to BTK (5B12). It can be used for WB,IP assays with tag free, in the background of Human.

HY-P82515

CD83 Antibody (YA2260)

CD83; CD83 antigen; hCD83; B-cell activation protein; cell surface protein HB15; CD antigen CD83
WB Human, Mouse, Rat

HY-P80722

IL-4 Antibody (YA343) IL4; Interleukin-4; IL-4; B-cell stimulatory factor 1; BSF-1; Binetrakin; Lymphocyte stimulatory factor 1; Pitrakinra	WB	Transfected
IL-4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 17 kDa, targeting to IL-4. It can be used for WB assays with tag free, in the background of Transfected.

HY-P80723

IL-6 Antibody IL6; IFNB2; Interleukin-6; IL-6; B-cell stimulatory factor 2; BSF-2; CTL differentiation factor; CDF; Hybridoma growth factor; Interferon beta-2; IFN-beta-2	WB, IHC-P, ELISA	Human
IL-6 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 24 kDa, targeting to IL-6. It can be used for WB,IHC-P,ELISA assays with tag free, in the background of Human.

HY-P80606

CD79a Antibody CD79A; IGA; MB1; B-cell antigen receptor complex-associated protein alpha chain; Ig-alpha; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein; CD antigen CD79a	WB, IHC-F, IHC-P, ICC/IF	Human
CD79a Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to CD79a. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P81522

CD22 Antibody (YA1267) CD22; SIGLEC2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD antigen CD22	IHC-P	Human

HY-P80454

Phospho-BTK(Y223) Antibody BTK(Y223); BTK (phospho Y223); p-BTK (phospho Y223); Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton’s Tyrosine Kinase; Btk; BTK_HUMAN; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; XLA.	WB, IHC-P, IHC-F, ICC, IF	Human
Phospho-BTK(Y223) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Phospho-BTK(Y223). It can be used for WB, IHC-P, IHC-F, ICC, IF assays with tag free, in the background of Human.

HY-P81235

IL-4 Antibody Interleukin-4; IL4; IL 4; B cell growth factor 1; B cell IgG differentiation factor; B cell Stimulatory Factor 1; BCGF 1; BCGF1; Binetrakin; BSF 1; BSF1; HCGF; Hodgkin’s cell Growth Factor; IA Inducing Factor; IGG1 induction factor; Il4e12; Interleukin 4; Interleukin 4, isoform 1; Interleukin4; Lymphocyte stimulatory factor 1; Macrophage fusion factor; Mast cell growth factor 2; MCGF2; MFF; MGC79402; Pitrakinra; T cell growth factor 2; TCGF2; IL4_MOUSE; B-cell stimulatory factor 1; BSF-1.	WB; ELISA; IHC-P; IHC-F; IF	Human, Mouse, Rat
IL-4 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 14 kDa, targeting to IL-4. It can be used for WB、ELISA、IHC-P、IHC-F、IF assays with tag free, in the background of Transfected.

HY-P82852

PAX5 Antibody (YA2597)

PAX5; Paired box protein Pax-5; B-cell-specific transcription factor; BSAP
WB, IHC-P, ICC/IF, FC Human, Mouse

HY-P81765

BAFF Antibody (YA1510) TNFSF13B; BAFF; BLYS; TALL1; TNFSF20; ZTNF4; Tumor necrosis factor ligand superfamily member 13B; B lymphocyte stimulator; BLyS; B-cell-activating factor; BAFF; Dendritic cell-derived TNF-like molecule; TNF- and APOL-related leukocyte expressed ligand 1; TALL-1; CD257	FC, ELISA	Human

HY-P82250

RanBP9 Antibody (YA1995) B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.	WB, ICC/IF	Human, Mouse, Rat

HY-P81438

Nampt Antibody (YA1183)

Nicotinamide phosphoribosyltransferase; NAmPRTase; Nampt; Pre-B-cell colony-enhancing factor 1; Pre-B cell-enhancing factor; Visfatin
IHC-P Human

HY-P83443

SDF1 Antibody (YA3188) CXCL12; SDF1; SDF1A; SDF1B; Stromal cell-derived factor 1; SDF-1; hSDF-1; C-X-C motif chemokine 12; Intercrine reduced in hepatomas; IRH; hIRH; Pre-B cell growth-stimulating factor; PBSF	WB, ICC/IF	Human

Cat. No.	Product Name		Classification

HY-161080

4'-Ethynyl-2'-deoxycytidine		Alkynes
4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks